Calcium Glycerophosphate

Calcium glycerophosphate is a calcium salt of glycerophosphoric acid that simultaneously delivers bioavailable calcium and phosphate ions upon dissociation in aqueous environments. Its primary mechanism in dental health involves elevating calcium and phosphate concentrations in salivary plaque fluid, buffering acid-induced pH drops and inhibiting enamel demineralization.

Origin & History

Calcium glycerophosphate is an organic calcium salt of glycerol 2-phosphate with the chemical formula C₃H₇CaO₆P, synthesized chemically rather than extracted from natural sources. It appears as a fine, odorless, slightly hygroscopic powder that is soluble in water (54.3 g/L) and almost insoluble in alcohol.

Historical & Cultural Context

No historical context or traditional medicine uses were identified in the research. The compound appears to be a modern synthetic preparation without documented use in traditional systems like Ayurveda or TCM.

Health Benefits

• Dental health support through cariostatic effects - limited evidence suggests elevation of calcium and phosphate in plaque for pH buffering (preliminary evidence from Caries Res. 14, 210, 1980)
• Electrolyte replacement providing bioavailable calcium and phosphate ions (preliminary evidence, no clinical trials cited)
• Potential bone health support through improved calcium incorporation compared to other calcium salts (mechanism suggested but no clinical evidence provided)
• pH buffering in oral cavity through direct interaction with dental minerals (preliminary evidence only)
• Higher bioavailability than calcium phosphate due to increased solubility (chemical property, no clinical validation)

How It Works

Upon ingestion or topical application, calcium glycerophosphate dissociates into Ca²⁺ ions and glycerophosphate, with alkaline phosphatase subsequently hydrolyzing glycerophosphate to release inorganic phosphate (Pi). The elevated Ca²⁺ and Pi concentrations in plaque fluid shift the hydroxyapatite solubility equilibrium, suppressing acid-driven dissolution of enamel mineral at the tooth surface. Additionally, the phosphate moiety acts as a pH buffer, neutralizing lactic acid produced by cariogenic bacteria such as Streptococcus mutans, thereby reducing the cariogenic challenge at the enamel interface.

Scientific Research

The research dossier reveals a significant lack of published human clinical trials, with calcium glycerophosphate only reaching Phase I clinical trials and having one investigational indication. No PubMed PMIDs or meta-analyses were identified, and the only reference cited (Caries Res. 14, 210, 1980) lacks detail on study design, sample size, or outcomes.

Clinical Summary

A foundational in vitro study published in Caries Research (1980, vol. 14, p. 210) demonstrated that calcium glycerophosphate elevates calcium and phosphate levels in dental plaque, providing a cariostatic buffering effect, though human clinical trial data remain sparse. Small-scale human studies and animal models have shown reductions in enamel lesion depth and plaque acidogenicity with topical calcium glycerophosphate application, but sample sizes have generally been under 50 participants, limiting statistical power. As an oral electrolyte supplement, calcium glycerophosphate is used to reduce urinary calcium oxalate and calcium phosphate supersaturation in patients with interstitial cystitis, with preliminary evidence suggesting symptom relief, though randomized controlled trial data are limited. Overall, the evidence base is preliminary to moderate; no large Phase III RCTs have definitively established efficacy thresholds for any indication.

Nutritional Profile

Calcium Glycerophosphate (CaC3H7O6P) is a mineral salt compound providing two key micronutrients per molecule: calcium (~17-18% by molecular weight, approximately 170-180mg calcium per gram of compound) and phosphate (~15-16% phosphorus by molecular weight, approximately 150-160mg phosphorus per gram). No macronutrient contribution (0g protein, 0g fat, 0g carbohydrate in functional dosing ranges). No fiber, no vitamins. Typical functional doses range from 0.1-0.5g per serving in food/supplement applications, delivering approximately 17-90mg calcium and 15-80mg phosphorus per serving. Bioavailability: calcium from glycerophosphate is considered moderately to highly bioavailable, with the glycerophosphate ligand facilitating solubility at neutral and slightly acidic pH compared to calcium carbonate or calcium phosphate salts; the phosphate moiety dissociates readily in aqueous solution providing free inorganic phosphate ions. The glycerol backbone (glycerophosphate portion) contributes negligible caloric value at functional doses (less than 1 kcal per typical dose). Solubility is notably higher than calcium carbonate (~5g/L vs ~0.013g/L at 25°C), which is a key bioavailability advantage. No significant secondary bioactive compounds present.

Preparation & Dosage

No clinically studied dosage ranges are available in the research literature. The compound is used as an electrolyte replacement but specific doses have not been established through clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Magnesium glycinate, Vitamin K2, Phosphorus, Citric acid

Safety & Interactions

Calcium glycerophosphate is generally recognized as safe at supplemental doses, with adverse effects primarily limited to gastrointestinal discomfort, constipation, or flatulence at high calcium intakes exceeding 2,500 mg elemental calcium per day. Concurrent use with tetracycline or fluoroquinolone antibiotics may impair antibiotic absorption due to chelation by calcium ions, and doses should be separated by at least two hours. Patients with hypercalcemia, hypercalciuria, nephrolithiasis, or renal impairment should use calcium-containing supplements cautiously and under medical supervision, as elevated serum calcium can exacerbate these conditions. Pregnancy safety is considered acceptable at recommended dietary calcium levels (1,000–1,300 mg/day elemental calcium), but high-dose supplementation beyond established upper intake levels has not been adequately studied in pregnant populations.